Combination therapy having antioxydant properties

1 . A method of treating a disease involving oxidative stress comprising the administration, to a subject in need of treatment, a combination product comprising:

(i) elafibranor, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic acid, or a pharmaceutically acceptable salt of elafibranor or 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic acid, and

(ii) a compound selected from the group consisting of Nitazoxanide (NTZ), Tizoxanide (TZ), and a pharmaceutically acceptable salt of NTZ or TZ;

wherein the disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, tardive dyskinesia, epilepsy, acute diseases of the central nervous system, spinal cord injuries, brain trauma, ischemic brain damage, lung ischemia-reperfusion injury, stroke, and rheumatoid arthritis.

2 . The method according to claim 1 , wherein component (i) is elafibranor or a pharmaceutically acceptable salt thereof.

3 . The method according to claim 1 , wherein component (ii) is Nitazoxanide (NTZ), or a pharmaceutically acceptable salt of NTZ.

4 . The method according to claim 1 , wherein component (i) is elafibranor or a pharmaceutically acceptable salt thereof and component (ii) is NTZ or a pharmaceutically acceptable salt thereof.

5 . The method according to claim 1 , wherein said combination product is a pharmaceutical composition comprising component (i) and component (ii).

6 . The method according to claim 1 , wherein said combination product is a kit comprising:

a first pharmaceutical composition comprising component (i); and

a second pharmaceutical composition comprising component (ii).

7 . The method according to claim 1 , wherein component (i) and component (ii) are formulated for oral administration.

8 . The method according to claim 1 , wherein component (i) and component (ii) are formulated in a pill, a tablet or a suspension for oral ingestion.